Neurocrine Study Demonstrates Ingrezza Efficacy in Tardive Dyskinesia
Recent clinical data indicates that Neurocrine Biosciences' Ingrezza successfully improved symptoms in patients suffering from tardive dyskinesia.
Neurocrine Biosciences has released study results demonstrating that its flagship treatment, Ingrezza, effectively improved symptoms associated with tardive dyskinesia.
Tardive dyskinesia is a neurological condition characterized by involuntary, repetitive movements of the body, frequently linked to long-term usage of psychiatric medications. The findings add to the clinical profile of Ingrezza as a therapeutic option for managing these symptoms.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →